IP Library › Granted Patent US 12,704,459
Granted Patent B2
US 12,704,459 · App. 17/849,917 · Granted Aug 11, 2026

Methods, compositions, and kits for assay signal amplification

Inventors: John Kenten (Boyds, MD); George Sigal (Rockville, MD); Alexander K. Tucker-Schwartz (Bethesda, MD)
Assignee: MESO SCALE TECHNOLOGIES, LLC.
G01N21/6428C07F15/0053C12Q1/6816G01N21/66G01N33/533G01N33/582G01N2021/6439
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,704,459
App. No.
17/849,917
Filed
Jun 27, 2022
Granted
Aug 11, 2026
Kind
B2
Art Unit
1682
USPC
435/6.11
Abstract

The invention relates to methods, compositions, kits, and assay systems for assay signal amplification. Also provided herein is a signal amplification reagent, wherein the signal amplification reagent is an antibody or antigen-binding fragment thereof.

Claims (67)

1 . A method of detecting an analyte of interest in a sample, comprising:

(I):

a. contacting a first complex that comprises (A) a first detectable label, wherein the first detectable label is an electrochemiluminescent (ECL) label, and (B) the analyte of interest, with a signal amplification reagent that specifically binds to the first detectable label, wherein the signal amplification reagent comprises a nucleic acid probe, thereby forming a second complex comprising the first complex and the signal amplification reagent;

b. extending the nucleic acid probe to form an extended sequence; and

c. measuring the amount of extended sequence, thereby detecting the analyte of interest;

or

(II):

d. forming a first complex on a surface comprising the analyte of interest, a capture reagent that specifically binds to the analyte, wherein the capture reagent is immobilized on the surface or wherein the capture reagent is capable of being immobilized to the surface; and a detection reagent that specifically binds to the analyte and that comprises a first nucleic acid probe;

e. extending the first nucleic acid probe to form a first extended sequence comprising a first anchoring region, wherein the first anchoring region binds a first anchoring reagent that is immobilized on the surface;

f. binding the first extended sequence to a first labeled probe comprising a first detectable label, wherein the first detectable label is an electrochemiluminescent (ECL) label;

g. contacting the first labeled probe bound to the first extended sequence with a signal amplification reagent that specifically binds to the first detectable label, wherein the signal amplification reagent comprises a second nucleic acid probe, thereby forming a second complex comprising the signal amplification reagent and the first labeled probe;

h. extending the second nucleic acid probe to form a second extended sequence comprising a second anchoring region, wherein the second anchoring region binds a second anchoring reagent that is immobilized on the surface; and;

i. measuring the amount of (I) the second extended sequence or (II) the first extended sequence and the second extended sequence bound to the surface, thereby detecting the analyte of interest.

2 . The method of claim 1 , wherein the first complex of (I) is on a surface, optionally wherein the surface comprises a particle or a well of a multi-well plate.

3 . The method of claim 2 , wherein the first complex of (I) comprises:

a capture reagent that specifically binds to the analyte, wherein the capture reagent is immobilized on the surface prior to the contacting of (a); and

a detection reagent that specifically binds to the analyte and that comprises the first detectable label.

4 . The method of claim 3 , wherein the capture reagent, the detection reagent, and the signal amplification reagent each comprises an antibody or antigen-binding fragment thereof, antigen, ligand, receptor, oligonucleotide, hapten, epitope, mimotope, or aptamer.

5 . The method of claim 3 , wherein the first detectable label is linked to the detection reagent via a conjugation linker.

6 . The method of claim 2 , wherein the first complex of (I) comprises:

a capture reagent that specifically binds to the analyte, wherein the capture reagent is immobilized on the surface prior to the contacting of (a);

a first detection reagent that specifically binds to the analyte; and

a second detection reagent that specifically binds to the analyte,

wherein the first complex comprises at least two first detectable labels, and wherein each of the first detection reagent and the second detection reagent comprises one of the at least two first detectable labels.

7 . The method of claim 6 , wherein the first detectable label is linked to the second detection reagent via a conjugation linker, and wherein the signal amplification reagent is capable of binding simultaneously to the first detectable label on the first detection reagent and to the first detectable label on the second detection reagent.

8 . The method of claim 2 , wherein the surface comprises an electrode, and the measuring further comprises applying a voltage waveform to the electrode to generate an electrochemiluminescence signal; or

wherein the surface comprises a particle, and the method further comprises collecting the particle on an electrode, and the measuring further comprises applying a voltage waveform to the electrode to generate an electrochemiluminescence signal.

9 . The method of claim 1 ,

wherein the extending of (b), (e), or (h) comprises polymerase chain reaction (PCR), ligase chain reaction (LCR), strand displacement amplification (SDA), self-sustained synthetic reaction (3SR), isothermal amplification, or combination thereof; and

when the extending of (b), (e), or (h) comprises PCR, the extending comprises binding the nucleic acid probe to a template oligonucleotide and extending the nucleic acid probe by PCR;

when the extending of (b), (e), or (h) comprises isothermal amplification, the extending comprises binding the nucleic acid probe to a template oligonucleotide, forming a circular template, and extending the nucleic acid probe by rolling circle amplification (RCA).

10 . The method of claim 9 , wherein the first complex of (I) is on a surface, and wherein the surface comprises an anchoring reagent that is immobilized on the surface prior to or during the extending of (b), wherein the anchoring reagent binds to an anchoring region of the extended sequence.

11 . The method of claim 10 , wherein the anchoring reagent and the anchoring region comprise complementary oligonucleotides, and

wherein the measuring of (c) comprises measuring the amount of extended sequence bound to the surface via the anchoring reagent.

12 . The method of claim 1 , wherein the first complex of (I) comprises at least two first detectable labels;

wherein the signal amplification reagent is a first signal amplification reagent, and the contacting of (a) further comprises contacting the first complex with a second signal amplification reagent that comprises a nucleic acid probe, wherein the first and second signal amplification reagents each binds to a distinct first detectable label, and the second complex comprises the first complex and the first and second signal amplification reagents.

13 . The method of claim 12 , wherein the extending of (b) comprises:

binding one or both of the nucleic acid probes of the first and second signal amplification reagents to a template oligonucleotide, forming a circular template, and extending one or both nucleic acid probes by RCA, wherein:

each nucleic acid probe is bound to a distinct template oligonucleotide; a circular template is formed from each template oligonucleotide; and each nucleic acid probe is extended by RCA; or

both nucleic acid probes are contacted with two template oligonucleotides, wherein each template oligonucleotide binds to a portion of each nucleic acid probe; the two template oligonucleotides are ligated to form a circular template; and one or both of the nucleic acid probes are extended by RCA.

14 . The method of claim 13 , wherein the nucleic acid probes of the first and second signal amplification reagents comprise or consist of a same sequence.

15 . The method of claim 1 , wherein the method further comprises, prior to the contacting of (a) or (g) detecting the first complex, wherein detecting the first complex comprises measuring the amount of the first detectable label.

16 . The method of claim 1 , wherein the signal amplification reagent is an antibody or antigen-binding fragment thereof comprising an antigen binding domain specific to an electrochemiluminescent (ECL) label or to an ECL label and a conjugation linker.

17 . The method of claim 1 , wherein the measuring comprises binding the extended sequence of (I) to a labeled probe or binding the second extended sequence of (II) to a second labeled probe, wherein the labeled probe or the second labeled probe comprises a second detectable label, and measuring the amount of (i) the second detectable label or (ii) the first and second detectable labels on the surface.

18 . The method of claim 17 , wherein the second detectable label is capable of being measured using light scattering, optical absorbance, fluorescence, chemiluminescence, electrochemiluminescence, bioluminescence, phosphorescence, radioactivity, magnetic field, or combinations thereof.

19 . The method of claim 18 , wherein each of the first detectable label and the second detectable label is an ECL label, and wherein the ECL label of the first and/or the second detectable label comprises an organometallic complex comprising at least one substituted bipyridine ligand, wherein the substituted bipyridine ligand comprises at least one sulfonate group, and optionally wherein:

the organometallic complex comprises at least two substituted bipyridine ligands, wherein each substituted bipyridine ligand comprises at least one sulfonate group;

the organometallic complex comprises ruthenium, osmium, or rhenium; and/or

the substituted bipyridine ligand is a compound of Formula I:

20 . The method of claim 18 , wherein each of the first detectable label and the second detectable label is an ECL label, and wherein the ECL label of the first and the second detectable label is a compound of Formula II:

or

wherein the first detectable label comprises a compound of Formula II, and the second detectable label comprises a compound of any one of Formulas III, IV, V, or VI:

wherein X is a phosphate, a carbonate, a borate, or combination thereof;

or

wherein the first detectable label comprises a compound of Formula III, and the second detectable label comprises a compound of any one of Formulas II, IV, V, or VI; or

wherein the first detectable label comprises a compound of Formula IV, and the second detectable label comprises a compound of any one of Formulas II, III, V, or VI; or

wherein the first detectable label comprises a compound of Formula V, and the second detectable label comprises a compound of any one of Formulas II, III, IV, or VI; or

wherein the first detectable label comprises a compound of Formula VI, and the second detectable label comprises a compound of any one of Formulas II, III, IV, or V.

21 . The method of claim 1 , wherein the surface of (II) comprises an electrode, and the measuring further comprises applying a voltage waveform to the electrode to generate an electrochemiluminescence signal; or

wherein the surface of (II) comprises a particle, and the method further comprises collecting the particle on an electrode, and the measuring further comprises applying a voltage waveform to the electrode to generate an electrochemiluminescence signal.

22 . The method of claim 1 , wherein, in the first complex of (II), the capture reagent, the detection reagent, and the signal amplification reagent each comprises an antibody or antigen-binding fragment thereof, antigen, ligand, receptor, oligonucleotide, hapten, epitope, mimotope, or aptamer.

23 . The method of claim 1 , wherein the first extended sequence of (II) binds to at least two first labeled probes that each comprise a first detectable label;

wherein the signal amplification reagent of (II) is a first signal amplification reagent, and the contacting of (g) further comprises contacting the first extended sequence with a second signal amplification reagent that comprises a third nucleic acid probe, wherein the first and second signal amplification reagents each binds to a distinct first detectable label, and the second complex comprises the first and second signal amplification reagents each bound to a first labeled probe.

24 . The method of claim 23 , wherein the extending of (h) comprises:

binding one or both of the second and third nucleic acid probes of the first and second signal amplification reagents to a template oligonucleotide, forming a circular template, and extending one or both second nucleic acid probes by RCA, wherein:

each second nucleic acid probe is bound to a distinct template oligonucleotide; a circular template is formed from each template oligonucleotide; and each second nucleic acid probe is extended by RCA; or

both second nucleic acid probes are contacted with two template oligonucleotides, wherein each template oligonucleotide binds to a portion of each second nucleic acid probe; the two template oligonucleotides are ligated to form a circular template; and one or both of the second nucleic acid probes are extended by RCA.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2022
From: KENTEN, JOHN; SIGAL, GEORGE; TUCKER-SCHWARTZ, ALEXANDER K.
To: MESO SCALE TECHNOLOGIES, LLC.
Reel/Frame 061445/0337 →
Continuity (2)
Provisional Application 63215660 · Jun 28, 2021
Related Publication 20230020070A1 · Jan 19, 2023
References Cited (400)
US 3996345A · Ullman et al. · 1976 [cited by applicant]
US 4235601A · Deutsch et al. · 1980 [cited by applicant]
US 4342566A · Theofilopoulos et al. · 1982 [cited by applicant]
US 4442204A · Greenquist et al. · 1984 [cited by applicant]
US 4595661A · Cragle et al. · 1986 [cited by applicant]
US 4988617A · Landegren et al. · 1991 [cited by applicant]
US 5026653A · Lee et al. · 1991 [cited by applicant]
US 5028535A · Buechler et al. · 1991 [cited by applicant]
US 5093268A · Leventis et al. · 1992 [cited by applicant]
US 5147806A · Kamin et al. · 1992 [cited by applicant]
US 5185243A · Ullman et al. · 1993 [cited by applicant]
US 5200314A · Urdea · 1993 [cited by applicant]
US 5238808A · Bard et al. · 1993 [cited by applicant]
US 5240863A · Shibue et al. · 1993 [cited by applicant]
US 5308754A · Kankare et al. · 1994 [cited by applicant]
US 5324457A · Zhang et al. · 1994 [cited by applicant]
US 5561043A · Cantor et al. · 1996 [cited by applicant]
US 5589136A · Northrup et al. · 1996 [cited by applicant]
US 5591581A · Massey et al. · 1997 [cited by applicant]
US 5597910A · Gudibande et al. · 1997 [cited by applicant]
US 5620851A · Axelrod et al. · 1997 [cited by applicant]
US 5629156A · Shah et al. · 1997 [cited by applicant]
US 5629157A · Goodman · 1997 [cited by applicant]
US 5635347A · Link et al. · 1997 [cited by applicant]
US 5641623A · Martin · 1997 [cited by applicant]
US 5643713A · Liang et al. · 1997 [cited by applicant]
US 5652107A · Lizardi et al. · 1997 [cited by applicant]
US 5656731A · Urdea · 1997 [cited by applicant]
US 5660991A · Lakowicz et al. · 1997 [cited by applicant]
US 5665539A · Sano et al. · 1997 [cited by applicant]
US 5667974A · Birkenmeyer et al. · 1997 [cited by applicant]
US 5679519A · Oprandy · 1997 [cited by applicant]
US 5705402A · Leland et al. · 1998 [cited by applicant]
US 5714089A · Bard et al. · 1998 [cited by applicant]
US 5714320A · Kool · 1998 [cited by applicant]
US 5731147A · Bard et al. · 1998 [cited by applicant]
US 5759773A · Tyagi et al. · 1998 [cited by applicant]
US 5776672A · Hashimoto et al. · 1998 [cited by applicant]
US 5786141A · Bard et al. · 1998 [cited by applicant]
US 5837446A · Cozzette et al. · 1998 [cited by applicant]
US 5846485A · Leland et al. · 1998 [cited by applicant]
US 5854033A · Lizardi · 1998 [cited by applicant]
US 5866434A · Massey et al. · 1999 [cited by applicant]
US 5871921A · Landegren et al. · 1999 [cited by applicant]
US 5925517A · Tyagi et al. · 1999 [cited by applicant]
US 5942391A · Zhang et al. · 1999 [cited by applicant]
US 6048687A · Kenten et al. · 2000 [cited by applicant]
US 6054274A · Sampson et al. · 2000 [cited by applicant]
US 6066448A · Wohlstadter et al. · 2000 [cited by applicant]
US 6077668A · Kool · 2000 [cited by applicant]
US 6136268A · Ala-Kleme · 2000 [cited by applicant]
US 6140135A · Landegren et al. · 2000 [cited by applicant]
US 6143495A · Lizardi et al. · 2000 [cited by applicant]
US 6183960B1 · Lizardi · 2001 [cited by applicant]
US 6207369B1 · Wohlstadter et al. · 2001 [cited by applicant]
US 6210884B1 · Lizardi · 2001 [cited by applicant]
US 6214552B1 · Heroux et al. · 2001 [cited by applicant]
US 6235472B1 · Landegren et al. · 2001 [cited by applicant]
US 6287824B1 · Lizardi · 2001 [cited by applicant]
US 6291187B1 · Kingsmore et al. · 2001 [cited by applicant]
US 6316229B1 · Lizardi et al. · 2001 [cited by applicant]
US 6316607B1 · Massey et al. · 2001 [cited by applicant]
US 6323009B1 · Lasken et al. · 2001 [cited by applicant]
US 6329150B1 · Lizardi et al. · 2001 [cited by applicant]
US 6344329B1 · Lizardi · 2002 [cited by applicant]
US 6368801B1 · Faruqi · 2002 [cited by applicant]
US 6444661B1 · Barton et al. · 2002 [cited by applicant]
US 6468741B1 · Massey et al. · 2002 [cited by applicant]
US 6479233B1 · Bard et al. · 2002 [cited by applicant]
US 6511809B2 · Baez et al. · 2003 [cited by applicant]
US 6531283B1 · Kingsmore et al. · 2003 [cited by applicant]
US 6558928B1 · Landegren · 2003 [cited by applicant]
US 6569647B1 · Zhang et al. · 2003 [cited by applicant]
US 6632609B2 · Lizardi · 2003 [cited by applicant]
US 6646118B2 · Kwiatkowski et al. · 2003 [cited by applicant]
US 6673533B1 · Wohlstadter et al. · 2004 [cited by applicant]
US RE38442E · Zhang et al. · 2004 [cited by applicant]
US 6709815B1 · Dong et al. · 2004 [cited by applicant]
US 6797474B2 · Lizardi · 2004 [cited by applicant]
US 6808939B2 · Sigal et al. · 2004 [cited by applicant]
US 6878515B1 · Landegren · 2005 [cited by applicant]
US 6939720B2 · Chandler et al. · 2005 [cited by applicant]
US 6977722B2 · Wohlstadter et al. · 2005 [cited by applicant]
US 7074564B2 · Landegren et al. · 2006 [cited by applicant]
US 7192703B2 · Sun et al. · 2007 [cited by applicant]
US 7306904B2 · Landegren et al. · 2007 [cited by applicant]
US 7314711B2 · Richter et al. · 2008 [cited by applicant]
US 7320860B2 · Landegren et al. · 2008 [cited by applicant]
US 7351528B2 · Landegren · 2008 [cited by applicant]
US 7618776B2 · Lizardi · 2009 [cited by applicant]
US 7790388B2 · Landegren et al. · 2010 [cited by applicant]
US 7807448B2 · Glezer et al. · 2010 [cited by applicant]
US 7842246B2 · Wohlstadter et al. · 2010 [cited by applicant]
US 7883848B2 · Ericsson · 2011 [cited by applicant]
US 7883849B1 · Dahl · 2011 [cited by applicant]
US 7914983B2 · Palaniappan et al. · 2011 [cited by applicant]
US 7932060B2 · Nadeau et al. · 2011 [cited by applicant]
US 8013134B2 · Fredriksson · 2011 [cited by applicant]
US 8053188B2 · Gullberg et al. · 2011 [cited by applicant]
US 8080393B2 · Koch et al. · 2011 [cited by applicant]
US 8163499B2 · Singh et al. · 2012 [cited by applicant]
US 8222047B2 · Duffy et al. · 2012 [cited by applicant]
US 8236574B2 · Duffy et al. · 2012 [cited by applicant]
US 8268554B2 · Schallmeiner · 2012 [cited by applicant]
US 8338776B2 · Walt et al. · 2012 [cited by applicant]
US 8343526B2 · Billadeau et al. · 2013 [cited by applicant]
US 8741559B2 · Treiber et al. · 2014 [cited by applicant]
US 8770471B2 · Cong et al. · 2014 [cited by applicant]
US 9499573B2 · Bergmann et al. · 2016 [cited by applicant]
US 9618510B2 · Aghvanyan et al. · 2017 [cited by applicant]
US 9714937B2 · Dunaway et al. · 2017 [cited by applicant]
US 9731297B2 · Glezer et al. · 2017 [cited by applicant]
US 9777338B2 · Glezer et al. · 2017 [cited by applicant]
US 9921166B2 · Glezer et al. · 2018 [cited by applicant]
US 9976177B2 · Terbrueggen · 2018 [cited by applicant]
US 10114015B2 · Glezer et al. · 2018 [cited by applicant]
US 10184884B2 · Anderson et al. · 2019 [cited by applicant]
US 10189023B2 · Glezer et al. · 2019 [cited by applicant]
US 10201812B2 · Glezer et al. · 2019 [cited by applicant]
US 10272436B2 · Glezer et al. · 2019 [cited by applicant]
US 10281678B2 · Chamberlin et al. · 2019 [cited by applicant]
US 10408823B2 · Aghvanyan · 2019 [cited by examiner]
US 10908157B2 · Aghvanyan · 2021 [cited by examiner]
US 11242570B2 · Glezer · 2022 [cited by applicant]
US 11525825B2 · Aghvanyan et al. · 2022 [cited by applicant]
US 11697840B2 · Glezer · 2023 [cited by examiner]
US 12359264B2 · Glezer et al. · 2025 [cited by applicant]
US 12411131B2 · Aghvanyan · 2025 [cited by examiner]
US 12553887B2 · Kenten et al. · 2026 [cited by applicant]
US 20010041340A1 · Kingsmore · 2001 [cited by examiner]
US 20010053519A1 · Fodor et al. · 2001 [cited by applicant]
US 20020035247A1 · Kwiatkowski et al. · 2002 [cited by applicant]
US 20020051986A1 · Baez et al. · 2002 [cited by applicant]
US 20020064779A1 · Landegren et al. · 2002 [cited by applicant]
US 20020102592A1 · Landegren · 2002 [cited by applicant]
US 20020127658A1 · Amouyal · 2002 [cited by applicant]
US 20020155490A1 · Skinner et al. · 2002 [cited by applicant]
US 20030077670A1 · Cheng et al. · 2003 [cited by applicant]
US 20040022677A1 · Wohlstadter et al. · 2004 [cited by applicant]
US 20040023207A1 · Polansky · 2004 [cited by applicant]
US 20040023271A1 · Kum et al. · 2004 [cited by applicant]
US 20040121382A1 · Liu et al. · 2004 [cited by applicant]
US 20040142323A1 · Boyde · 2004 [cited by applicant]
US 20040189311A1 · Glezer et al. · 2004 [cited by applicant]
US 20040209261A1 · Keys et al. · 2004 [cited by applicant]
US 20040248103A1 · Feaver et al. · 2004 [cited by applicant]
US 20040265897A1 · Lizardi · 2004 [cited by applicant]
US 20050003432A1 · Hall et al. · 2005 [cited by applicant]
US 20050009015A1 · Gregg et al. · 2005 [cited by applicant]
US 20050009050A1 · Nadeau · 2005 [cited by applicant]
US 20050014140A1 · Erikson et al. · 2005 [cited by applicant]
US 20050052646A1 · Wohlstadter et al. · 2005 [cited by applicant]
US 20050142033A1 · Glezer et al. · 2005 [cited by applicant]
US 20050282158A1 · Landegren · 2005 [cited by applicant]
US 20050287526A1 · Landegren et al. · 2005 [cited by applicant]
US 20060078894A1 · Winkler et al. · 2006 [cited by applicant]
US 20070154899A1 · Coull et al. · 2007 [cited by applicant]
US 20070161029A1 · Li et al. · 2007 [cited by applicant]
US 20070259381A1 · Rissin et al. · 2007 [cited by applicant]
US 20070259385A1 · Rissin et al. · 2007 [cited by applicant]
US 20070259448A1 · Rissin et al. · 2007 [cited by applicant]
US 20080188638A1 · Breitenkamp et al. · 2008 [cited by applicant]
US 20090011943A1 · Drmanac et al. · 2009 [cited by applicant]
US 20090176318A1 · Kolpashchikov · 2009 [cited by applicant]
US 20090178934A1 · Jarvius et al. · 2009 [cited by applicant]
US 20090191553A1 · Hendrickson · 2009 [cited by applicant]
US 20090203155A1 · Chiku · 2009 [cited by applicant]
US 20100075862A1 · Duffy et al. · 2010 [cited by applicant]
US 20100129819A1 · Hu et al. · 2010 [cited by applicant]
US 20100261292A1 · Glezer et al. · 2010 [cited by applicant]
US 20110022331A1 · Clinton et al. · 2011 [cited by applicant]
US 20110027772A1 · Ahn et al. · 2011 [cited by applicant]
US 20110177054A1 · Gibbings et al. · 2011 [cited by applicant]
US 20110212537A1 · Rissin et al. · 2011 [cited by applicant]
US 20120196774A1 · Fournier et al. · 2012 [cited by applicant]
US 20120252692A1 · Kutyavin · 2012 [cited by applicant]
US 20120289428A1 · Duffy et al. · 2012 [cited by applicant]
US 20130059741A1 · Weiner · 2013 [cited by applicant]
US 20130171066A1 · Sellegren et al. · 2013 [cited by applicant]
US 20130323756A1 · Tullis et al. · 2013 [cited by applicant]
US 20140087379A1 · Bashkirov et al. · 2014 [cited by applicant]
US 20140194311A1 · Gullberg · 2014 [cited by applicant]
US 20140272939A1 · Aghvanyan et al. · 2014 [cited by applicant]
US 20140274775A1 · Glezer et al. · 2014 [cited by applicant]
US 20140315189A1 · Glezer et al. · 2014 [cited by applicant]
US 20150044674A1 · Fredriksson et al. · 2015 [cited by applicant]
US 20170089892A1 · Aghvanyan · 2017 [cited by examiner]
US 20170168047A1 · Aghvanyan et al. · 2017 [cited by applicant]
US 20170362668A1 · Glezer et al. · 2017 [cited by applicant]
US 20180074082A1 · Glezer et al. · 2018 [cited by applicant]
US 20190002971A1 · Koslover et al. · 2019 [cited by applicant]
US 20190011441A1 · Glezer · 2019 [cited by applicant]
US 20190391140A1 · Aghvanyan et al. · 2019 [cited by applicant]
US 20190391170A1 · Kochar et al. · 2019 [cited by applicant]
US 20210190778A1 · Aghvanyan et al. · 2021 [cited by applicant]
US 20220033918A1 · Glezer · 2022 [cited by applicant]
US 20220099661A1 · Kenten et al. · 2022 [cited by applicant]
US 20220357318A1 · Aghvanyan et al. · 2022 [cited by applicant]
US 20230175043A1 · Kenten et al. · 2023 [cited by applicant]
US 20230407380A1 · Glezer et al. · 2023 [cited by applicant]
US 20240229110A1 · Kenten et al. · 2024 [cited by applicant]
US 20240368676A1 · Kenten et al. · 2024 [cited by applicant]
US 20250060361A1 · Aghvanyan et al. · 2025 [cited by applicant]
US 20250327141A1 · Glezer et al. · 2025 [cited by applicant]
US 20250362291A1 · Aghvanyan et al. · 2025 [cited by applicant]
CN 1446050A · 2003 [cited by applicant]
CN 101198707A · 2008 [cited by applicant]
CN 101988920A · 2011 [cited by applicant]
CN 102317779A · 2012 [cited by applicant]
CN 103703145B · 2014 [cited by applicant]
CN 104114718A · 2014 [cited by applicant]
CN 108374052A · 2018 [cited by applicant]
EP 1985714A1 · 2008 [cited by applicant]
EP 2500435A1 · 2012 [cited by applicant]
JP H04262799A · 1992 [cited by applicant]
JP H08505050A · 1996 [cited by applicant]
JP H10504105A · 1998 [cited by applicant]
JP H11508040A · 1999 [cited by applicant]
JP 2000300267A · 2000 [cited by applicant]
JP 2005521409A · 2005 [cited by applicant]
JP 2005522405A · 2005 [cited by applicant]
JP 2006511807A · 2006 [cited by applicant]
JP 2007525661A · 2007 [cited by applicant]
JP 2009106220A · 2009 [cited by applicant]
JP 2009222712A · 2009 [cited by applicant]
JP 2020529585A · 2020 [cited by applicant]
KR 1020130003127A · 2013 [cited by applicant]
WO 9005910A1 · 1990 [cited by applicant]
WO 9117442A1 · 1991 [cited by applicant]
WO 9414961A1 · 1994 [cited by applicant]
WO 9535390A1 · 1995 [cited by applicant]
WO 9635812A1 · 1996 [cited by applicant]
WO 9932662A1 · 1997 [cited by applicant]
WO 9736931A1 · 1997 [cited by applicant]
WO 9812539A1 · 1998 [cited by applicant]
WO 9857154A1 · 1998 [cited by applicant]
WO 9914599A1 · 1999 [cited by applicant]
WO 9949079A1 · 1999 [cited by applicant]
WO 9958962A1 · 1999 [cited by applicant]
WO 9963347A2 · 1999 [cited by applicant]
WO 0003233A1 · 2000 [cited by applicant]
WO 0004193A1 · 2000 [cited by applicant]
WO 0135100A2 · 2001 [cited by applicant]
WO 0138580A2 · 2001 [cited by applicant]
WO 0184146A2 · 2001 [cited by applicant]
WO 03022028A2 · 2003 [cited by applicant]
WO 03033722A2 · 2003 [cited by applicant]
WO 2004045543A2 · 2004 [cited by applicant]
WO 2004061131A1 · 2004 [cited by applicant]
WO 2004094456A2 · 2004 [cited by applicant]
WO 2005059509A2 · 2005 [cited by applicant]
WO 2009029073A1 · 2009 [cited by applicant]
WO 2009067009A1 · 2009 [cited by applicant]
WO 2009092386A2 · 2009 [cited by applicant]
WO 2010059820A1 · 2010 [cited by applicant]
WO 2010118411A2 · 2010 [cited by applicant]
WO 2011047087A2 · 2011 [cited by applicant]
WO 2011143583A1 · 2011 [cited by applicant]
WO 2012007511A1 · 2012 [cited by applicant]
WO 2012049316A1 · 2012 [cited by applicant]
WO 2012060083A1 · 2012 [cited by applicant]
WO 2012104261A1 · 2012 [cited by applicant]
WO 2012152942A1 · 2012 [cited by applicant]
WO 2012160083A1 · 2012 [cited by applicant]
WO 2013113699A1 · 2013 [cited by applicant]
WO 2014031984A1 · 2014 [cited by applicant]
WO 2014160192A1 · 2014 [cited by applicant]
WO 2014165061A1 · 2014 [cited by applicant]
WO 2015175856A1 · 2015 [cited by applicant]
WO 2016164477A1 · 2016 [cited by applicant]
WO 2017015636A1 · 2017 [cited by applicant]
WO 2017093271A1 · 2017 [cited by applicant]
WO 2018017156A1 · 2018 [cited by applicant]
WO 2020092835A1 · 2020 [cited by applicant]
WO 2020142313A1 · 2020 [cited by applicant]
WO 2022051485A2 · 2022 [cited by applicant]
Buijs et al., “Interference by antiruthenium antibodies in the Roche thyroid-stimulating hormone assay,” Ann Clin Biochem 48(3):276-281 (2011). [cited by applicant]
Gessl et al., “Anti-ruthenium antibodies mimic macro-TSH in electrochemiluminescent immunoassay,” Clin Chem Lab Med 52(11):1589-1594 (2014). [cited by applicant]
Lin et al., “A Sulfhydryl-Reactive Ruthenium (II) Complex and Its Conjugation to Protein G as a Universal Reagent for Fluorescent Immunoassays,” PLoS One 7(4):e36086 (2012). [cited by applicant]
Ohba et al., “Falsely elevated thyroid hormone levels caused by antiruthenium interference in the Elecsys assay resembling the syndrome of inappropriate secretion of thyrotropin,” Endocr J 59(8):663-667 (2012). [cited by applicant]
Sargeant et al., “Platform Perfection,” Medical Product Outsourcing, May 17, 2010. Accessed at <https://www.mpo-mag.com/issues/2010-05/view_features/platform-perfection>. [cited by applicant]
Zhu et al., “Electrochemiluminescence Immunosensor Based on Au Nanocluster and Hybridization Chain Reaction Signal Amplification for Ultrasensitive Detection of Cardiac Troponin I,” ACS Sens 4(10):2778-2785 (2019). [cited by applicant]
International Search Report in International Application No. PCT/US2022/035068, dated Jan. 12, 2022. [cited by applicant]
Adler et al., “Detection of rViscumin in plasma samples by immuno-PCR,” Biochemical and Biophysical Research Communications 300:757-763 (2003). [cited by applicant]
Andras et al., “Strategies for Signal Amplification in Nucleic Acid Detection,” Molecular Biotechnology 19:29-44 (2001). [cited by applicant]
Baner et al., “Signal Amplification of Padlock Probes by Rolling Circle Replication,” Nucleic Acids Research 26(22):5073-5078 (1998). [cited by applicant]
Break et al., “Utilization of the N-PLEX™ Platform for the Detection of Antisense Oligonucleotides (ASOs) in Plasma,” Molecular Therapy; 2020 ASGCT Annual Meeting Abstracts, 28(4-S1):549 (2020). [cited by applicant]
Chan, “General principle of immunoassay.” Immunoassay: A Practical Guide, pp. 1-23 (1987). [cited by applicant]
Dahl et al., “Circle-to-Circle Amplification for Precise and Sensitive DNA Analysis,” Proceedings of the National Academy of Sciences USA 101(13):4548-4553 (2004). [cited by applicant]
Darmanis et al., “Self-Assembly of Proximity Probes for Flexible and Modular Proximity Ligation Assays,” BioTechniques 46(4):443-450 (2007). [cited by applicant]
Darmanis et al., “Sensitive Plasma Protein Analysis by Microparticle-Based Proximity Ligation Assays,” Molecular Cell Proteomics 9(2): 327-335 (2010). [cited by applicant]
Darmanis et al., “ProteinSeq: High-Performance Proteomic Analyses by Proximity Ligation and Next Generation Sequencing,” PLOS One 6(9) p. e25583 (2011). [cited by applicant]
Dean et al., “Rapid Amplification of Plasmid and Phage DNA Using Phi29 DNA Polymerase and Multiply-Primed Rolling Circle Amplification,” Genome Research 1095-1099 (2001). [cited by applicant]
Ericsson et al., “A Dual-Tag Microarray Platform for High-Performance Nucleic Acid and Protein Analyses,” Nucleic Acids Research 36(8):e45 (2008). [cited by applicant]
Faruqi et al., “High-Throughput Genotyping of Single Nucleotide Polymorphisms With Rolling Circle Amplification,” BMC Genomics 2:4 (2001). [cited by applicant]
Fire et al., “Rolling Replication of Short DNA Circles,” Proceedings of the National Academy of Sciences USA 92:4641-4645 (1995). [cited by applicant]
Flamme et al., “Applications of Ruthenium Complexes Covalently Linked to Nucleic Acid Derivatives,” [cited by applicant]
Fredriksson et al., “Multiplexed Protein Detection by Proximity Ligation for Cancer Biomarker Validation,” Nature Methods 4(4):327-329 (2007). [cited by applicant]
Fredriksson et al., Supplementary Table 2, “Multiplexed Protein Detection by Proximity Ligation for Cancer Biomarker Validation,” Nature Methods 4(4):327-329 (2007). [cited by applicant]
Fredriksson et al., “Protein Detection Using Proximity-Dependent DNA Ligation Assays,” Nature Biotechnology 20:473-477 (2002). [cited by applicant]
Gajadhar et al., “A Proximity Ligation Assay Using Transiently Transfected, Epitope-Tagged Proteins: Application for In Situ Detection of Dimerized Receptor Tyrosine Kinases,” Bio Techniques 48(2):145-151 (2010). [cited by applicant]
Ghesquiere et al., “What Does the Future Hold for Photo-Oxidizing Ru [cited by applicant]
Gill et al., “Nucleic Acid Isothermal Amplification Technologies—A Review,” Nucleosides, Nucleotides, and Nucleic Acids 27:224-243 (2008). [cited by applicant]
Griffiths et al., “Miniaturising the Laboratory in Emulsion Droplets,” Trends in Biotechnology 24(9):395-402 (2006). [cited by applicant]
Gu et al., “Protein tag-mediated conjugation of oligonucleotides to recombinant affinity binders for proximity ligation,” New Biotechnology 30(2):144-152 (2013). [cited by applicant]
Gullberg M. et al., “A Sense of Closeness: Protein Detection by Proximity Ligation,” Current Opinion in Biotechnology 14:82-86 (2003). [cited by applicant]
Gustafsdottir et al., “Detection of Individual Microbial Pathogens by Proximity Ligation,” Clinical Chemistry 52(6):1152-1160 (2006). [cited by applicant]
He, “Development of on-chip proximity ligation assay with in situ single molecule sequencing readout,” Masters Dissertation, Uppsala University (2011). [cited by applicant]
Heyduk et al., “Molecular Pincers: Antibody-Based Homogeneous Protein Sensors,” Analytical Chemistry 80(13):5152-5159 (2008). [cited by applicant]
Hochman et al., “An Active Antibody Fragment (Fv) Composed of the Variable Portions of Heavy and Light Chains,” Biochemistry 12(6):1130-1135 (1973). [cited by applicant]
Holder et al., “Assignment of Neisseria Meningitidis Serogroup A and C Class-Specific Anticapsular Antibody Concentrations to the New Standard Reference Serum CDC1992,” Clinical and Diagnostic Laboratory Immunology 2(2)… [cited by applicant]
Hu et al., “Quantitation of Femtomolar Protein Levels Via Direct Readout With the Electrochemical Proximity Assay,” Journal of the American Chemical Society 134(16):7066-7072 (2012). [cited by applicant]
Jeong et al., “Isothermal DNA Amplification In Vitro: The Helicase-Dependent Amplification System,” Cellular and Molecular Life Sciences 66:3325-3336 (2009). [cited by applicant]
Kopecky et al., “Quantification of HDL Proteins, Cardiac Events, and Mortality in Patients with Type 2 Diabetes on Hemodialysis,” Clin J Am Soc Nephrol 10:224-231 (2015). [cited by applicant]
Kumar et al., “Development & evaluation of biotinylated DNA probe for clinical diagnosis of chikungunya infection in patients' acute phase serum & CSF samples,” Indian J Med Res. 138:117-124 (2013). [cited by applicant]
Landegren et al., “A Ligase-Mediated Gene Detection Technique,” Science 241:1077:1080 (1988). [cited by applicant]
Lee et al., “Diffractometric Detection of Proteins using Microbead-based Rolling Circle Amplification,” Analytical Chemistry 82(1):197 (2010). [cited by applicant]
Leuchowius et al., “Parallel Visualization of Multiple Protein Complexes in Individual Cells in Tumor Tissue,” Molecular & Cellular Proteomics 12:1563-1571 (2013). [cited by applicant]
Lizardi et al., “Mutation Detection and Single-Molecule Counting Using Isothermal Rolling-Circle Amplification,” Nature Genetics 19:225-232 (1998). [cited by applicant]
Marchese et al., “Optimization and Validation of a Multiplex, Electrochemiluminescence-Based Detection Assay for the Quantitation of Immunoglobulin G Serotype-Specific Antipneumococcal Antibodies in Human Serum,” Clinic… [cited by applicant]
Mendoza et al., “High-Throughput Microarray-Based Enzyme-Linked Immunosorbent Assay (ELISA),” BioTechniques 27(4):778-788 (1999). [cited by applicant]
Meso Scale Discovery Inc: “Sandwich Immunogenicity Assays for Protein Drugs,” Meso Scale Discovery, Inc. Rockville, Maryland USA (Nov. 1, 2012). [cited by applicant]
Nallur et al., “Signal Amplification by Rolling Circle Amplification on DNA Microarrays,” Nucleic Acids Research 29(23):e118 (2001). [cited by applicant]
Niemeyer et al., “Fluorometric Polymerase Chain Reaction (PCR) Enzyme-Linked Immunosorbent Assay for Quantification of Immuno-PCR Products in Microplates,” Analytical Biochemistry 246:140-145 (1997). [cited by applicant]
Nilsson et al., “Padlock Probes: Circularizing Oligonucleotides for Localized DNA Detection,” Science 265:2085-2088 (1994). [cited by applicant]
Nolan et al., “Multiplexed and Microparticle-Based Analyses: Quantitative Tools for the Large-Scale Analysis of Biological Systems,” Cytometry Part A 69A:318-325 (2006). [cited by applicant]
Nong et al., “Solid-phase Proximity Ligation Assays for Individual or Parallel Protein Analyses with Readout via Real-Time PCR or Sequencing,” Nat. Protocols, 8(6): 1234-1248 (2013). [cited by applicant]
Nordengrahn et al., “Evaluation of a Novel Proximity Ligation Assay for the Sensitive and Rapid Detection of Foot-and-Mouth Disease Virus,” Veterinary Microbiology 127:227-236 (2008). [cited by applicant]
Olink Bioscience: DuoLink II Probemaker PLUS, Duolink II Probemaker MINUS, Product Insert Doc No. 0564 (2012). [cited by applicant]
Porter et al., “Subunits of Immunoglobulins and Their Relationship to Antibody Specificity,” Journal of Cellular Physiology 67(Sup 1):51-64 (1966). [cited by applicant]
Ribas et al., “Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential,” Circ Res 95(8):7… [cited by applicant]
Samiotaki et al., “Dual-Color Detection of DNA Sequence Variants by Ligase-Mediated Analysis,” Genomics 20:238-242 (1994). [cited by applicant]
Schallmeiner et al., “Sensitive Protein Detection Via Triple-Binder Proximity Ligation Assays,” Nature Methods 4(2):135-137 (2007). [cited by applicant]
Schweitzer et al., “Multiplexed Protein Profiling on Microarrays by Rolling-Circle Amplification,” Nature Biotechnology 20:359-365 (2002). [cited by applicant]
Schweitzer et al., “Immunoassays With Rolling Circle DNA Amplification: A Versatile Platform for Ultrasensitive Antigen Detection,” Proceedings of the National Academy of Sciences USA 97(18):10113-10119 (2000). [cited by applicant]
Shibayama et al., “Nucleic acid (DNA/RNA) quantitative method,” [cited by applicant]
Soderberg et al., “Direct observation of individual endogenous protein complexes in situ by proximity ligation,” Nature Methods 3(12):995-1000 (2006). [cited by applicant]
Soderberg et al., “Characterizing Proteins and Their Interactions in Cells and Tissues Using the In Situ Proximity Ligation Assay,” Methods 45:227-232 (2008). [cited by applicant]
Spits et al., “Whole-Genome Multiple Displacement Amplification from Single Cells,” Nature Protocols 1(4):1965-1970 (2006). [cited by applicant]
Tavoosidana et al. “Multiple Recognition Assay Reveals Prostasomes as Promising Plasma Biomarkers for Prostate Cancer,” PNAS 108(21):8809-8814 (2011). [cited by applicant]
Vincent et al., “Helicase-Dependent Isothermal DNA Amplification,” European Molecular Biology Organization 5(8):795-800 (2004). [cited by applicant]
Vuoriluoto et al., “Spatio-Temporal Composition of the Mitotic Chromosomal Passenger Complex Detected Using In Situ Proximity Ligation Assay,” Molecular Oncology 5:105-111 (2011). [cited by applicant]
Watanabe et al., “Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid … [cited by applicant]
Weibrecht et al., “Proximity Ligation Assays: A Recent Addition to the Proteomics Toolbox,” Expert Review of Proteomics 7(3):401-409 (2010). [cited by applicant]
Yamada et al., “Detection of Methicillin-Resistant [cited by applicant]
Zhang et al., “Amplification of Circularizable Probes for the Detection of Target Nucleic Acids and Proteins,” Clinica Chimica Acta 363:61-70 (2006). [cited by applicant]
Zhang et al., “Ruthenium Polypyridine Complexes Combined with Oligonucleotides for Bioanalysis: A Review,” Molecules 19:11933-11987 (2014). [cited by applicant]
Zhou H. et al., “Two-Color, Rolling-Circle Amplification on Antibody Microarrays for Sensitive, Multiplexed Serum-Protein Measurements,” Genome Biology 5:R28 (2004). [cited by applicant]
International Search Report in PCT/US2012/064263, dated Mar. 15, 2013. [cited by applicant]
International Search Report in PCT/US2014/024279, dated Jul. 17, 2014. [cited by applicant]
International Search Report in PCT/US2014/026010, dated Jul. 7, 2014. [cited by applicant]
International Search Report in PCT/US2015/030925, dated Aug. 27, 2015. [cited by applicant]
International Search Report in PCT/US2020/020288, dated May 14, 2020. [cited by applicant]
International Search Report in PCT/US2021/048854, dated Feb. 24, 2023. [cited by applicant]
International Search Report in PCT/US2023/084737, dated May 15, 2024. [cited by applicant]
Restriction Requirement in U.S. Appl. No. 14/357,653, dated Jul. 31, 2015. [cited by applicant]
Non-Final Office Action in U.S. Appl. No. 14/357,653, dated Oct. 26, 2015. [cited by applicant]
Final Office Action in U.S. Appl. No. 14/357,653, dated Jun. 22, 2016. [cited by applicant]
Non-Final Office Action in U.S. Appl. No. 14/357,653, dated Jan. 31, 2017. [cited by applicant]
Non-Final Office Action in U.S. Appl. No. 15/696,953, dated Mar. 27, 2019. [cited by applicant]
Final Office Action in U.S. Appl. No. 15/696,953, dated Nov. 25, 2019. [cited by applicant]
Final Office Action in U.S. Appl. No. 15/696,953, dated Jun. 15, 2020. [cited by applicant]
Non-Final Office Action in U.S. Appl. No. 15/696,953, dated Mar. 9, 2021. [cited by applicant]
Notice of Allowance issued in U.S. Appl. No. 15/696,953, dated Sep. 27, 2021. [cited by applicant]
Non-Final Office Action in U.S. Appl. No. 17/504,937, dated Apr. 17, 2023. [cited by applicant]
Final Office Action in U.S. Appl. No. 17/504,937, dated Oct. 16, 2023. [cited by applicant]
Non-Final Office Action in U.S. Appl. No. 17/504,937, dated Sep. 25, 2024. [cited by applicant]
Non-Final Office Action in U.S. Appl. No. 14/206,284, dated Oct. 16, 2015. [cited by applicant]
Final Office Action in U.S. Appl. No. 14/206,284, dated Jul. 6, 2016. [cited by applicant]
Non-Final Office Action in U.S. Appl. No. 15/440,191, dated Jun. 20, 2019. [cited by applicant]
Final Office Action in U.S. Appl. No. 15/440,191, dated Dec. 16, 2019. [cited by applicant]
Final Office Action in U.S. Appl. No. 15/440,191, dated May 22, 2020. [cited by applicant]
Non-Final Office Action in U.S. Appl. No. 17/132,380, dated Nov. 24, 2023. [cited by applicant]
Final Office Action in U.S. Appl. No. 17/132,380, dated May 3, 2024. [cited by applicant]
Advisory Action in U.S. Appl. No. 17/132,380, dated Jul. 29, 2024. [cited by applicant]
Notice of Allowance in U.S. Appl. No. 17/132,380, dated Aug. 7, 2024. [cited by applicant]
Non-Final Office Action in U.S. Appl. No. 14/208,040, dated Dec. 30, 2015. [cited by applicant]
Final Office Action in U.S. Appl. No. 14/208,040, dated Oct. 11, 2016. [cited by applicant]
Non-Final Office Action in U.S. Appl. No. 14/208,040, dated Feb. 7, 2017. [cited by applicant]
Final Office Action in U.S. Appl. No. 14/208,040, dated Jul. 27, 2017. [cited by applicant]
Non-Final Office Action in U.S. Appl. No. 14/208,040, dated Jan. 16, 2018. [cited by applicant]
Restriction Requirement in U.S. Appl. No. 16/136,498, dated Mar. 19, 2021. [cited by applicant]
Non-Final Office Action issued in U.S. Appl. No. 16/136,498, dated Oct. 13, 2021. [cited by applicant]
Final Office Action issued in U.S. Appl. No. 16/136,498, dated Apr. 20, 2022. [cited by applicant]
Advisory Action issued in U.S. Appl. No. 16/136,498, dated Jul. 5, 2022. [cited by applicant]
Non-Final Office Action in U.S. Appl. No. 16/136,498, dated Oct. 14, 2022. [cited by applicant]
Notice of Allowance in U.S. Appl. No. 16/136,498, dated Feb. 21, 2023. [cited by applicant]
Notice of Allowance in U.S. Appl. No. 16/136,498, dated Mar. 1, 2023. [cited by applicant]
Non-Final Office Action in U.S. Appl. No. 15/311,309, dated May 4, 2018. [cited by applicant]
Final Office Action in U.S. Appl. No. 15/311,309, dated Oct. 26, 2018. [cited by applicant]
Notice of Allowance issued in U.S. Appl. No. 15/311,309, dated May 9, 2019. [cited by applicant]
Restriction Requirement in U.S. Appl. No. 16/564,208, dated Nov. 10, 2020. [cited by applicant]
Non-Final Office Action in U.S. Appl. No. 16/564,208, dated May 10, 2021. [cited by applicant]
Final Office Action issued in U.S. Appl. No. 16/564,208, dated Oct. 6, 2021. [cited by applicant]
Advisory Action issued in U.S. Appl. No. 16/564,208, dated Jan. 27, 2022. [cited by applicant]
Notice of Allowance in U.S. Appl. No. 16/564,208, dated Apr. 25, 2022. [cited by applicant]
Supplemental Notice of Allowance in U.S. Appl. No. 16/564,208, dated May 18, 2022. [cited by applicant]
Supplemental Notice of Allowance in U.S. Appl. No. 16/564,208, dated Jul. 21, 2022. [cited by applicant]
Supplemental Notice of Allowance in U.S. Appl. No. 16/564,208, dated Aug. 17, 2022. [cited by applicant]
Restriction Requirement in U.S. Appl. No. 17/813,965, dated Mar. 19, 2024. [cited by applicant]